Identification of a putative binding site for [2′,5′-Bis-O-(tert-butyldimethylsilyl) -β-D-ribofuranosyl]-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase

Journal of Medicinal Chemistry

Volumn 44, Issue 12, 2001, Pages 1853-1865

  Rodriguez Barrios F ^a   Perez C ^a   Lobaton E ^b   Velazquez S ^b   Chamorro, C ^b   San Felix A ^b   Perez Perez M J ^b   Camarasa, M J ^b   Pelemans, H ^c   Balzarini, J ^c   Gago, F ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

[2',5' BIS O (TERT BUTYLDIMETHYLSILYL) BETA DEXTRO RIBOFURANOSYL] 3' SPIRO 5'' (4'' AMINO 1'',2'' OXATHIOLE 2'',2'' DIOXIDE)THYMINE DERIVATIVE; PROTEIN SUBUNIT; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DIMERIZATION; DRUG ACTIVITY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; SIMULATION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; BINDING SITES; CELL LINE; ELECTROSTATICS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; MUTAGENESIS, SITE-DIRECTED; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN SUBUNITS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE;

EID: 0035821586     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm001095i     Document Type: Article

References (70)

1. Structure-activity analyses of HIV-1 reverse transcriptase
2. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1
3. Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: Implications of conformational changes for polymerization and inhibition mechanisms
4. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA
5. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance
6. High resolution structures of HIV-1 RT from four RT-inhibitor complexes
7. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer
8. Chimeric HIV-1 and feline immunodeficiency virus reverse transcriptases: Critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerases
9. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer
10. Characterization of the dimerization process of HIV-1 reverse transcriptase heterodimer using intrinsic protein fluorescence
11. Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: A two step process
12. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections
13. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
14. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy
15. Mutations in retroviral genes associated with drug Resistance: 2000-2001 update
16. 2′,5′Bis-O-(tert-butyldimethylsilyl) -3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide) pyrimidine (TSAO) nucleoside analogues: Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase
17. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl] -3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)thymine (TSAO-T)
18. Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-O-(tertbutyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)] (TSAO) derivatives is determined by the mutation Glu138→Lys on the p51 subunit
19. Human immunodeficiency virus type 1-specific [2′,5′-bis-O(tert-butyldimethylsilyl) -β-D-ribofuranosyl]-3′-spiro-5″- (4″-amino1″,2″-oxathiole-2″,2″-dioxide)purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues
20. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-O- (tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)] β-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors
21. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[spiro[4″-amino-2″,2″dioxo-1″,2″ -oxathiole-5″,3′-[2′,5′-bis-O- (tert-butyldimethylsilyl)β-D-ribofaranosyl]]]-3-ethylthymine
22. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer
23. HIV-1 specific reverse transcriptase inhibitors: Why are TSAO-nucleosides so unique?
24. Novel 3′-spiro nucleoside analogues of TSAO-T. Part II. A comparative study based on NMR conformational analysis in solution and theoretical calculations
25. Synthesis and anti-HIV-1 activity of novel TSAO-T derivatives modified at the 2′- and 5′-positions of the sugar moiety
26. Regiospecific synthesis and antihuman immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkylcarbamoyl 1,2,3-triazoleTSAO analogues
27. Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase
28. Novel series of [ddN]-[TSAO-T] heterodimers as potential bi-functional inhibitors of HTV-1 RT. Studies in the linker and ddN region
29. Potential multifunctional inhibitors of HIV-1 reverse transcriptase. Novel [AZT]-[TSAO-T] and [d4T]-[TSAOT] heterodimers modified in the linker and in the dideoxynucleoside region
30. Conformational stability of dimeric HIV-1 and HIV-2 reverse transcriptases
31. A hot spot of binding energy in a hormone-receptor interface
32. Abbreviations and symbols for the description of conformations of polynucleotide chains
33. TSAO-analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-bis-O-(tert-butyldimethylsilyl) -βD-ribofuranosyl]-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide) pyrimidine and pyrimidine-modified nucleosides
34. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138
35. An improved method for the preparation of desoxopeptides: Reduction of endothiopeptides
36. Synthetically useful reactions with nickel boride. A review
37. Pyrimidine nucleosides. V. 2-Oxohexahydropyrimidines and their nucleosides
38. Nucleic acid components and their analogues. CLIX. Synthesis of some 2-pyrimidone nucleosides
39. Studies on organophosphorous compounds. XXI. The dimer of p-methoxyphenylthionophosphine sulfide as thiation reagent. A new route to thiocarboxamides
40. Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders
41. Synthesis and antiHIV-1 activity of base modified analogues of 3′-azido-2′,3′dideoxythymidine (AZT)
42. Synthesis of 4,5dihydro-1H-imidazoles from 1,5-dihydro-2H-imidazoles using "nickel boride"
43. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2′,5′-bis-O-(tert-butyldimethylsilyl) -3′-spiro-5″- (4″-amino1″,2″-oxathiole-2″,2″-dioxide] (TSAO)
44. An enzymatically active chimeric HIV-1 reverse transcriptase (RT) with the RNase-H domain of murine leukemia virus RT exists as a monomer
45. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
46. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives
47. The interpretation of protein structures: Estimation of static accessibility
48. Hydrophobic bonding and accessible surface area in proteins
49. Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2)
50. Comparison of simple potential functions for simulating liquid water
51. A wellbehaved electrostatic potential based method using charge restraints for deriving atomic charges: The RESP model
52. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules
53. 2 with manoalide
54. Automated docking using Lamarckian genetic algorithm and an empirical binding free energy function
55. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules
56. ′-azido-3′-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes
57. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor
58. Focusing of electric fields in the active site of Cu-Zn superoxide dismutase: Effects of ionic strength and amino-acid modification
59. Comparative binding energy analysis of HIV-1 protease inhibitors: Incorporation of solvent effects and validation as a powerful tool in receptor-based drug design
60. The computer program LUDI: A new method for the de novo design of enzyme inhibitors
61. LUDI: A rule-based automatic design of new substituents for enzyme inhibitor leads
62. Sensitivity of (138 Glu → Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors
63. Mutational analysis of Tyr-318 within the nonnucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase